2. Gene
  3. KIT - KIT proto-oncogene, receptor tyrosine kinase Gene

KIT - KIT proto-oncogene, receptor tyrosine kinase Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

中文名称：K IT 原癌基因， 受体酪氨酸激酶

种属: Macaca fascicularis

基因 ID: 102137242 | 基因类型: protein coding

关于 KIT

Primary_assembly 5: 79,352,500-79,442,954 reverse strand.Macaca_fascicularis_6.0:CM021943.1

This gene has 3 transcripts (splice variants), 206 orthologues and 55 paralogues.

KIT 基因产物(8)

mRNA Protein Name
XM_005555275.3 XP_005555332.1 mast/stem cell growth factor receptor Kit isoform X6
XM_045392612.1 XP_045248547.1 mast/stem cell growth factor receptor Kit isoform X4
XM_005555274.3 XP_005555331.1 mast/stem cell growth factor receptor Kit isoform X3
XM_005555273.3 XP_005555330.1 mast/stem cell growth factor receptor Kit isoform X2
XM_045392614.1 XP_045248549.1 mast/stem cell growth factor receptor Kit isoform X7
XM_015450467.2 XP_015305953.1 mast/stem cell growth factor receptor Kit isoform X8
XM_005555272.3 XP_005555329.1 mast/stem cell growth factor receptor Kit isoform X1
XM_015450466.2 XP_015305952.1 mast/stem cell growth factor receptor Kit isoform X5

KIT 蛋白结构

ig

ig: pfam00047 (215 - 305)

Ig

Ig: cd00096 (228 - 232)

Ig

Ig: cd00096 (266 - 277)

Ig

Ig: cd00096 (287 - 292)

Ig

Ig: cd00096 (300 - 303)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (311 - 317)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (311 - 411)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (321 - 326)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (329 - 339)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (343 - 350)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (352 - 355)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (358 - 363)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (372 - 381)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (388 - 396)

IgI_4_SCFR

IgI_4_SCFR: cd05860 (399 - 410)

Ig

Ig: cd00096 (426 - 502)

Ig

Ig: cd00096 (437 - 441)

Ig

Ig: cd00096 (470 - 478)

Ig

Ig: cd00096 (488 - 493)

PTKc_Kit

PTKc_Kit: cd05104 (553 - 928)

  • 0
  • 200
  • 400
  • 600
  • 800
  • 977 a.a.
蛋白主名 其他名称

mast/stem cell growth factor receptor Kit

v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog

相关产品

Approval
生物活性分子 (27)
目录号 产品名 作用方式
纯度 是否罕见病
HY-10201 Sorafenib 99.92% 是
HY-10981 Lenvatinib Inhibitor 99.84% 是
HY-16749 Pexidartinib 99.64% 是
HY-10331 Regorafenib 99.65% 是
HY-15463 Imatinib 99.95% 是
HY-13016 Cabozantinib 99.96% 是
HY-10230 Midostaurin 99.95% 是
HY-10208 Pazopanib 99.77% 是
HY-10201A Sorafenib Tosylate 99.91% 是
HY-50946 Imatinib Mesylate 99.98% 是
HY-101561 Avapritinib Inhibitor 99.94% 是
HY-112306 Ripretinib 99.33% 是
HY-10209 Masitinib 99.98% 是
HY-16749A Pexidartinib hydrochloride 99.89% 是
HY-10981A Lenvatinib mesylate Inhibitor 99.86% 是
HY-12009 Pazopanib Hydrochloride 99.88% 是
HY-12044 Cabozantinib S-malate 99.84% 是
HY-10331A Regorafenib monohydrate 99.96% 是
HY-13308 Regorafenib Hydrochloride 99.58% 是
HY-13904 Flumatinib Inhibitor 99.94% 否
HY-10209A Masitinib mesylate 99.83% 是
HY-13311A Infigratinib phosphate Inhibitor 99.74% 是
HY-10330A Toceranib phosphate Inhibitor 98.54% 否
HY-10330 Toceranib Inhibitor 96.86% 否
HY-B1684 Mebrofenin 99.88% 否
HY-10331B Regorafenib mesylate / 否
HY-13016A Cabozantinib hydrochloride / 否
Clinical Phase
生物活性分子 (28)
目录号 产品名 作用方式
纯度 Phase
HY-13905 Flumatinib mesylate Inhibitor 99.87% Phase 4
HY-16961 Sitravatinib Inhibitor 99.59% Phase 3
HY-50905 Dovitinib Inhibitor 99.94% Phase 3
HY-10205 Cediranib 99.58% Phase 3
HY-136256 Vimseltinib Inhibitor 99.08% Phase 3
HY-124526 Chiauranib Inhibitor 99.28% Phase 3
HY-13049 Cediranib maleate 99.84% Phase 3
HY-10228 Motesanib Inhibitor 99.96% Phase 3
HY-10207 Dovitinib lactate Inhibitor 99.62% Phase 3
HY-108713 Famitinib 98.43% Phase 3
HY-10229 Motesanib Diphosphate Inhibitor 99.64% Phase 3
HY-152839 Elenestinib Inhibitor 98.82% Phase 3
HY-16961A Sitravatinib malate Inhibitor / Phase 3
HY-B0062 Dovitinib lactate hydrate Inhibitor / Phase 3
HY-108713A Famitinib malate / Phase 3
HY-13024 Rebastinib 99.91% Phase 2
HY-109086 Edicotinib Inhibitor 98.78% Phase 2
HY-10206 Amuvatinib 99.47% Phase 2
HY-10202 Tandutinib 99.48% Phase 2
HY-10527 Telatinib Inhibitor 99.60% Phase 2
HY-109190 Seralutinib Inhibitor 99.77% Phase 2
HY-10527C Telatinib mesylate Inhibitor 99.46% Phase 2
HY-10202A Tandutinib hydrochloride 99.78% Phase 2
HY-10206A Amuvatinib hydrochloride Inhibitor / Phase 2
HY-15240 c-Kit-IN-1 Inhibitor 98.83% Phase 1
HY-10204 OSI-930 98.57% Phase 1
HY-12010 BMS-599626 Hydrochloride Inhibitor 99.68% Phase 1
HY-10251 BMS-599626 Inhibitor / Phase 1
Pre-clinical Phase
生物活性分子 (80)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-10514 BX795 99.06% 否
HY-132166 M4205 Inhibitor 99.47% 否
HY-145557 Bezuclastinib Inhibitor 98.59% 否
HY-101443 ISCK03 Inhibitor 99.50% 否
HY-10501 SU14813 Inhibitor 99.63% 否
HY-13838 PLX647 Inhibitor 99.79% 否
HY-131339 SP-96 Inhibitor 99.42% 否
HY-112802 AZD3229 Inhibitor 99.83% 否
HY-13894 Tyrphostin AG1296 99.69% 否
HY-G0017 N-Desmethyl imatinib 99.16% 否
HY-10873 N-Desethyl Sunitinib 99.63% 否
HY-10408 Ki20227 Inhibitor 99.17% 否
HY-I0678 Regorafénib N-oxyde (M2) 98.27% 否
HY-10501A SU14813 maleate Inhibitor 99.04% 否
HY-15463S1 Imatinib D4 99.97% 否
HY-18179 AZD2932 Inhibitor 99.04% 否
HY-13493 AC710 Inhibitor 98.56% 否
HY-112615 NAMPT inhibitor-linker 1 98.08% 否
HY-103274 PD180970 99.27% 否
HY-112452 SU11652 99.06% 否
HY-138813 N-Desethyl Sunitinib hydrochloride 99.77% 否
HY-15813 FIIN-1 Inhibitor 99.11% 否
HY-101219 VEGFR-IN-1 Inhibitor 98.42% 否
HY-10981S Lenvatinib-d4 Inhibitor 99.59% 否
HY-123450 S116836 99.65% 否
HY-13016S Cabozantinib-d6 98.14% 否
HY-15198 KG5 Inhibitor 99.79% 否
HY-112802A AZD3229 Tosylate Inhibitor 99.80% 否
HY-133980 O-Demethyl Lenvatinib / 否
HY-133980A O-Demethyl Lenvatinib hydrochloride 95.54% 否
HY-136201 Sodium Glucoheptonate ≥98.0% 否
HY-15463S2 Imatinib-d3 hydrochloride 95.19% 否
HY-18302 c-Kit-IN-5-1 Inhibitor 98.16% 否
HY-101034 CHMFL-ABL/KIT-155 / 否
HY-128589 CHMFL-KIT-033 Inhibitor / 否
HY-128602 c-Kit-IN-2 Inhibitor / 否
HY-148794 Risvodetinib Inhibitor / 否
HY-10873S N-Desethyl Sunitinib-d5 / 否
HY-10201S2 Sorafenib-13C,d3 / 否
HY-10208S Pazopanib-d6 / 否
HY-10208S1 Pazopanib-13C,d3 / 否
HY-10230S Midostaurin-d5 Inhibitor / 否
HY-103032 Multi-kinase inhibitor 1 Inhibitor 99.34% 否
HY-10330S Toceranib-d8 Inhibitor / 否
HY-10331S Regorafenib-d3 ≥98.0% 否
HY-10331S1 Regorafenib-13C,d3 / 否
HY-10981S1 Lenvatinib-d5 Inhibitor / 否
HY-110071 APcK110 Inhibitor / 否
HY-110272 Vatalanib succinate Inhibitor / 否
HY-117873 KBP-7018 Inhibitor / 否
HY-12009S Pazopanib-13C,d3 hydrochloride / 否
HY-13016S1 Cabozantinib-d4 / 否
HY-131275 Imatinib Impurity E 96.05% 否
HY-132451S (R,S)-4-Hydroxy Cyclophosphamide-d4 Preparation Kit / 否
HY-13342AS Apatinib-d8 free base / 否
HY-13645 Henatinib Inhibitor / 否
HY-13838A PLX647 dihydrochloride Inhibitor / 否
HY-13904S Flumatinib-d3 Inhibitor / 否
HY-139996 Pomalidomide-C5-Dovitinib / 否
HY-143894 FLT3-IN-11 Inhibitor / 否
HY-143895 FLT3-IN-12 Inhibitor / 否
HY-147864 c-Fms-IN-12 / 否
HY-149019 Antitumor agent-70 / 否
HY-149415 Multi-kinase-IN-5 Inhibitor / 否
HY-150026 Multi-kinase-IN-2 / 否
HY-15463S Imatinib-d8 99.85% 否
HY-156470 Multi-kinase-IN-6 / 否
HY-156619 Labuxtinib Inhibitor / 否
HY-15814 HG-7-85-01 / 否
HY-18317 JNJ-38158471 Inhibitor / 否
HY-18949 JI6 Inhibitor / 否
HY-50905S Dovitinib-d8 Inhibitor / 否
HY-G0017A N-Desmethyl imatinib mesylate / 否
HY-G0017S1 N-Desmethyl imatinib-d4 / 否
HY-I0678S Regorafénib N-oxyde-d3 (M2) / 否
HY-I0678S1 Regorafénib N-oxyde (M2)-13C,d3 / 否
HY-116116 Tafetinib Inhibitor / 否
HY-13493A AC710 Mesylate Inhibitor / 否
HY-112616 NAMPT inhibitor-linker 2 Inhibitor 98.11% 否
HY-111947 c-Fms-IN-6 Inhibitor / 否
抗体抑制剂 (1)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-P99462 Barzolvolimab Inhibitor 95.00% 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens KIT NCBI NCBI:3815
Mus musculus KIT NCBI NCBI:16590
Rattus norvegicus KIT NCBI NCBI:64030
Macaca mulatta KIT NCBI NCBI:696759